Nektar Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

26.02.14	Nektar Therapeutics Q4 Results Miss Estimates (RTTNews)
07.02.14	Bayer verklagt US-Unternehmen wegen Patentverletzung (Dow Jones)
23.01.14	Nektar Therapeutics Prices Public Offering Of 8.5 Mln Shares At $12.75/Share (RTTNews)
18.01.14	Nektar Presents Positive Clinical Data From Phase 1 Study Of Etirinotecan Pegol (RTTNews)
19.11.13	Nektar: FDA Accepts New Drug Application For Naloxegol - Quick Facts (RTTNews)
13.11.13	Baxter Int'l Closes Enrollment In Phase III Clinical Trial Of BAX 855 (RTTNews)
25.10.13	BABY Makes Big Leap, RIGL's Trial Flops, CLSN Warming Up To HEAT, NPSP On Watch (RTTNews)
16.10.13	Dividend Announcements, Earnings Release Scheduled, and Data Presentations from Clinical Studies - Research Report on Questcor, Regeneron, NPS, Incyte, and Nektar (PR Newswire)
07.10.13	Regulatory Approvals, Public Offerings and Clinical Trial Results - Research Report on Theravance, Synageva, Nektar, Clovis Oncology, and ImmunoGen (PR Newswire)
03.10.13	Nektar to Host Investor and Analyst R&D Day in New York City (PR Newswire)
02.10.13	Presentation on Research Findings, Recognitions, Clinical Trial Results, and Orphan Drug Designations - Research Report on Celgene, Biogen Idec, Amgen, Nektar, and Zalicus (PR Newswire)
27.09.13	Pre-market Movers For Sept 27 (BBRY, NKE, JCP, FINL, RDA, ZOLT, NKTR) (RTTNews)
27.09.13	NKTR Pained, SRPT Walks The Talk, Nu Skin Glows, APPY On Track, NEO On Watch (RTTNews)
27.09.13	Nektar Phase 2 Study Of NKTR-181 Fails To Meet Primary End-Point - Quick Facts (RTTNews)
27.09.13	After-market Movers For Sept 26 (NKE, UA, ACN, NKTR, JCP) (RTTNews)
26.09.13	Nektar Announces Preliminary Topline Results from Phase 2 Efficacy Study for NKTR-181 in Chronic Pain Patients with Osteoarthritis of the Knee (PR Newswire)
15.08.13	Pharma Companies Announce Investments in R&D, Ongoing Clinical Trials and Financial Results - Research Report on Alnylam, Infinity, Nektar, Sequenom, and Merrimack (PR Newswire)
09.08.13	NKTR Nearing Results, THLD Progresses, Wright Gets It Wrong, ZGNX On Watch (RTTNews)
08.08.13	Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013 (PR Newswire)
06.08.13	Strong Sales, Diversified Portfolio, and R&D Progress Boost Growth - Research Report on Teva, Auxilium, Nektar, Anika, and Vical (PR Newswire)
30.07.13	Nektar Completes Enrollment In BEACON Trial For Metastatic Breast Cancer (RTTNews)
30.07.13	Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer (PR Newswire)
25.05.07	Nektar Therapeutics President and CEO Howard Robin to Present at Bank of America 2007 Health Care Conference (Businesswire)
09.04.07	Innovative Pulmonary and PEGylation-Based Therapeutic Product Development Drives Business Strategy of Nektar Therapeutics (Businesswire)
28.02.07	Nektar Announces Financial Results for the Year and Fourth Quarter 2006 (Businesswire)
28.11.06	Advisory: BMO Capital Markets Focus on Healthcare Conference to Webcast Nektar Corporate Presentation (Businesswire)
14.09.06	Nektar Reports that Pfizer Announced New Analyses Showing that Exubera Is Effective in Diabetes Patients Who Have Respiratory Infections or Who are Exposed to Passive Cigarette Smoke (Businesswire)
12.09.06	Exubera Hailed as Innovation in Prestigious European and American Awards (Businesswire)
03.08.06	Nektar Announces Second Quarter 2006 Results (Businesswire)
20.07.06	Nektar Reports That Pfizer to Introduce Exubera in U.S. With a Comprehensive Education Program (Businesswire)
12.05.06	Bank of America Health Care Conference to Webcast Nektar Corporate Presentation (Businesswire)
10.05.06	Nektar Announces First Quarter 2006 Results (Businesswire)
28.02.06	Nektar Announces Financial Results for the Year and Fourth Quarter 2005 (Businesswire)
14.02.06	Nektar Announces That U.S. FDA Has Granted Orphan Drug Designation to the First Amphotericin B Inhalation Powder to Prevent Pulmonary Fungal Infections in Immunosuppressed Patients (Businesswire)
26.01.06	European Commission Approves Exubera(R) (Inhaled Human Insulin) for Treatment of Type 1 and Type 2 Diabetes (Businesswire)
03.11.05	Nektar Announces Third Quarter 2005 Financial Results (Businesswire)
29.09.05	Nektar Announces Inhaled Antibiotics Product to Prevent Pneumonia in Mechanically-Ventilated Patients (Businesswire)
26.07.05	Nektar Announces Newly-Created Diabetes Group and General Manager (Businesswire)
25.01.05	Bayer HealthCare and Nektar Therapeutics Collaborate to Develop Inhale (Businesswire)
24.01.05	Nektar and Zelos Announce Collaboration to Develop Inhaled Parathyroid (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

18.12.24		Schwacher Handel in New York: NASDAQ Composite implodiert letztendlich nahezu
04.12.24		Freundlicher Handel: NASDAQ Composite am Mittag im Plus
03.12.24		Aufschläge in New York: NASDAQ Composite beendet den Handel mit Gewinnen
27.11.24		Handel in New York: NASDAQ Composite verbucht am Mittwochnachmittag Abschläge
22.11.24		Börse New York: NASDAQ Composite stärker
22.11.24		Starker Wochentag in New York: Zum Handelsstart Gewinne im NASDAQ Composite
15.11.24		Schwacher Handel in New York: NASDAQ Composite verbucht zum Handelsende Abschläge
15.11.24		Zurückhaltung in New York: NASDAQ Composite verbucht nachmittags Verluste

18.12.24

Schwacher Handel in New York: NASDAQ Composite implodiert letztendlich nahezu

04.12.24

Freundlicher Handel: NASDAQ Composite am Mittag im Plus

03.12.24

Aufschläge in New York: NASDAQ Composite beendet den Handel mit Gewinnen

27.11.24

Handel in New York: NASDAQ Composite verbucht am Mittwochnachmittag Abschläge

22.11.24

Börse New York: NASDAQ Composite stärker

22.11.24

Starker Wochentag in New York: Zum Handelsstart Gewinne im NASDAQ Composite